Replagal (Agalsidase Alfa): Uses, Dosage & Side Effects

What Is Replagal and What Is It Used For?

Replagal contains the active substance agalsidase alfa, which is a recombinant human alpha-galactosidase A enzyme produced using gene-activation technology in a human cell line. This enzyme is structurally and functionally equivalent to the naturally occurring human enzyme that is deficient in patients with Fabry disease. By providing an exogenous source of this critical enzyme, Replagal enables the body to break down globotriaosylceramide (Gb3), the fatty substance that accumulates pathologically in cells when the natural enzyme is absent or insufficiently active.

Fabry disease (also known as Anderson-Fabry disease) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene, which encodes the alpha-galactosidase A enzyme. Because the condition is X-linked, it predominantly affects males, though heterozygous females can also develop clinically significant symptoms ranging from mild to severe. The disease was first described independently by dermatologists Johannes Fabry and William Anderson in 1898. It affects approximately 1 in 40,000 to 1 in 117,000 live births, although recent newborn screening studies suggest the prevalence may be higher when milder, late-onset variants are included.

Without adequate levels of alpha-galactosidase A, Gb3 accumulates progressively within the lysosomes of cells in virtually every organ system. The organs most severely affected include the kidneys, heart, and central and peripheral nervous systems. In the kidneys, Gb3 deposits in podocytes, tubular epithelial cells, and endothelial cells, leading to progressive proteinuria, declining glomerular filtration rate, and eventually end-stage renal disease. In the heart, accumulation causes left ventricular hypertrophy, arrhythmias, valvular disease, and cardiomyopathy. Cerebrovascular involvement can cause transient ischemic attacks and stroke, even in young adults. The peripheral nervous system is affected early, causing characteristic neuropathic pain (acroparesthesias) in the hands and feet, which is often one of the earliest symptoms in childhood.

Clinical trials have demonstrated that Replagal effectively reduces Gb3 levels in plasma and various tissues. In the pivotal randomized, double-blind, placebo-controlled trial (TKT-023), patients treated with agalsidase alfa 0.2 mg/kg every other week showed significant reductions in neuropathic pain, improved quality of life, and stabilization of renal function compared with placebo. Long-term open-label extension studies spanning up to 10 years have shown sustained benefits, including stabilization of renal function as measured by estimated glomerular filtration rate (eGFR), reduction in left ventricular mass in patients with cardiac hypertrophy, and improvement in pain and quality-of-life measures. The Fabry Registry and other post-marketing observational studies have confirmed these findings in a broader population of patients treated in routine clinical practice.

Replagal was first authorized by the European Medicines Agency (EMA) in 2001, making it one of the first enzyme replacement therapies available for Fabry disease. It is currently approved in the European Union, Japan, and many other countries worldwide. In the United States, agalsidase beta (Fabrazyme) is the approved ERT for Fabry disease, though agalsidase alfa has been used under compassionate use or clinical trial protocols. The availability of enzyme replacement therapy has fundamentally changed the management of Fabry disease, transforming it from an untreatable condition with relentless progression to one where disease stabilization and symptom improvement are achievable goals when treatment is initiated early.

What Should You Know Before Taking Replagal?

Contraindications

Replagal is contraindicated in patients with known severe hypersensitivity (anaphylactic reaction) to agalsidase alfa or to any of the excipients contained in the formulation. If a patient has previously experienced a life-threatening allergic reaction to the product, rechallenge should only be considered after very careful risk-benefit assessment and under close medical supervision with appropriate resuscitation facilities available.

Infusion-Associated Reactions

Infusion-associated reactions (IARs) are the most frequently reported adverse events with Replagal and occur in a substantial proportion of patients, particularly during the early months of treatment. These reactions may include fever, chills, flushing, headache, nausea, vomiting, tingling or numbness, chest tightness, sore throat, breathing difficulties, rapid heartbeat, and elevated or decreased blood pressure. Most infusion reactions are mild to moderate in severity and can be managed by temporarily slowing or interrupting the infusion, and by pre-treatment with antihistamines, antipyretics, or corticosteroids as needed.

In rare cases, severe hypersensitivity or anaphylactic-type reactions have been reported. Signs of a severe reaction may include sudden difficulty breathing, swelling of the face, lips, tongue or throat, widespread skin rash or hives, a rapid drop in blood pressure, and loss of consciousness. If anaphylaxis occurs, the infusion must be stopped immediately and appropriate emergency treatment must be administered. Because of this risk, Replagal infusions should initially be administered in a clinical setting equipped to handle severe allergic reactions. Patients who have experienced infusion reactions should be treated with caution and pre-medicated prior to subsequent infusions.

Antibody Development

As with all therapeutic proteins, patients may develop antibodies (immunoglobulin G, IgG) directed against agalsidase alfa. In clinical trials, approximately 24% of male patients developed IgG antibodies to agalsidase alfa. The presence of antibodies has been associated with a higher incidence of infusion-associated reactions in some studies. However, the clinical significance of antibodies with respect to treatment efficacy remains a subject of ongoing investigation. Some studies suggest that high antibody titers may partially neutralize enzyme activity and reduce the clinical benefit of treatment, while other data indicate that many antibody-positive patients continue to derive meaningful benefit from therapy. Regular monitoring of antibody status is recommended, particularly in patients who appear to be losing clinical response.

Patients with Renal Impairment

Fabry disease itself causes progressive renal impairment, and many patients presenting for treatment already have some degree of kidney dysfunction. The efficacy of enzyme replacement therapy may be reduced in patients with advanced renal disease. Clinical data suggest that the greatest benefit is achieved when treatment is initiated before irreversible kidney damage has occurred. Patients with significant proteinuria or reduced eGFR should be monitored closely, and concomitant renoprotective measures (such as ACE inhibitors or angiotensin receptor blockers) should be considered in accordance with current nephrology guidelines.

Patients with Cardiac Involvement

Patients with Fabry disease and significant cardiac involvement, including left ventricular hypertrophy, arrhythmias, or coronary artery disease, should be monitored carefully during and after infusions. The fluid volume associated with the infusion and the hemodynamic effects of the infusion itself may pose additional stress on a compromised cardiovascular system. Cases of cardiac ischemia and heart failure have been reported in patients with underlying Fabry cardiomyopathy during or shortly after infusion, though a direct causal relationship has not been established. Cardiac monitoring during infusion is recommended for patients with known significant cardiac disease.

Pregnancy and Breastfeeding

There is limited clinical data on the use of Replagal during pregnancy. Animal reproductive studies with agalsidase alfa have not shown direct harmful effects on pregnancy, embryonic or fetal development, parturition, or postnatal development. However, as with all medicines, caution is advised during pregnancy. Fabry disease can pose particular challenges during pregnancy due to the added cardiovascular and renal stress, and untreated Fabry disease may itself increase the risk of pregnancy complications. The decision to continue, start, or stop Replagal during pregnancy should be made on an individual basis in consultation with a specialist experienced in both Fabry disease and high-risk obstetrics.

It is not known whether agalsidase alfa is excreted in human breast milk. Because the enzyme is a large protein molecule, significant transfer into breast milk is considered unlikely, but caution should be exercised. Women who are breastfeeding should discuss the potential risks and benefits with their treating physician. The importance of the drug to the mother and the potential benefit of breastfeeding to the infant should both be considered when making this decision.

Children and Adolescents

Replagal is approved for use in children and adolescents aged 7 to 17 years at the same dose as adults (0.2 mg/kg every two weeks). Clinical experience in this age group, while more limited than in adults, has shown that the safety profile is generally similar. In one open-label study of 17 children aged 7 to 18 years, agalsidase alfa was well tolerated and demonstrated reductions in plasma Gb3 levels and improvements in neuropathic pain scores. For children aged 0 to 6 years, clinical data are very limited, and treatment in this age group should only be considered after careful evaluation by a specialist experienced in the management of Fabry disease. The potential benefits of early treatment must be weighed against the limited evidence base and the challenges of long-term intravenous therapy in very young children.

How Does Replagal Interact with Other Drugs?

Because agalsidase alfa is a recombinant protein that acts intracellularly within lysosomes, its potential for pharmacokinetic drug interactions is generally considered to be low compared with small-molecule drugs. It is not metabolized by cytochrome P450 enzymes and does not bind to plasma proteins in a manner that would displace other drugs. However, certain compounds have been identified that may theoretically interfere with the intracellular activity of the enzyme, and these potential pharmacodynamic interactions deserve careful consideration.

The drugs of concern are those that have the potential to inhibit intracellular alpha-galactosidase A activity. These agents may interfere with the binding of agalsidase alfa to its substrate (Gb3) within the lysosome, reduce the trafficking of the enzyme to lysosomes, or otherwise impair its catalytic function. Although the clinical significance of these theoretical interactions has not been established through formal interaction studies, prudence dictates that co-administration should be avoided when possible, and patients should inform their treating physician about all medications they are taking.

It is important to note that chloroquine is of particular relevance because it is a lysosomotropic agent that raises intralysosomal pH, which could impair the function of acid hydrolases such as alpha-galactosidase A. Amiodarone is a widely used antiarrhythmic drug that is known to accumulate in lysosomes and may interfere with lysosomal enzyme function. Given that many Fabry patients develop cardiac arrhythmias as part of their disease, the potential interaction between amiodarone and enzyme replacement therapy is clinically significant and should be discussed with the treating cardiologist. Alternative antiarrhythmic agents should be considered when appropriate.

Gentamicin, an aminoglycoside antibiotic, has been shown in vitro to inhibit certain lysosomal enzymes. While the clinical relevance of this finding during short courses of antibiotic therapy is uncertain, prolonged use of gentamicin in patients receiving Replagal should be avoided when suitable alternatives exist. Patients should always inform all healthcare providers involved in their care that they are receiving enzyme replacement therapy, so that potential interactions can be considered when prescribing new medications.

Additionally, patients receiving Replagal should be aware that the enzyme has no known interactions with common over-the-counter medications, including paracetamol (acetaminophen), ibuprofen, and other NSAIDs that may be used for managing pain. These medications are often used as premedication before infusions or for managing Fabry-related pain and can be used safely in conjunction with enzyme replacement therapy.

What Is the Correct Dosage of Replagal?

Treatment with Replagal should be initiated and supervised by a physician experienced in the management of Fabry disease or other lysosomal storage disorders. The dose is calculated based on the patient's actual body weight at each infusion visit. For example, a patient weighing 70 kg would receive 14 mg of agalsidase alfa (70 kg x 0.2 mg/kg = 14 mg), which corresponds to 14 ml of the 1 mg/ml concentrate. This volume is then withdrawn from the appropriate number of vials and added to a 100 ml bag of 0.9% sodium chloride for infusion.

Preparation and Administration

Each vial of Replagal contains 3.5 mg of agalsidase alfa in 3.5 ml of solution (concentration 1 mg/ml). The required volume should be calculated based on body weight and withdrawn from the appropriate number of vials using aseptic technique. The withdrawn volume is then slowly added to a 100 ml infusion bag of 0.9% sodium chloride solution. The bag should be gently mixed by inversion to avoid foaming of the protein solution. Do not shake. The diluted solution should be inspected visually before administration; do not use if the solution is discolored or contains visible particles.

The infusion should be delivered over 40 minutes using a controlled infusion rate. An in-line filter may be used if desired, as no significant protein loss has been observed with 0.2 micrometer filters in testing. Vital signs (blood pressure, heart rate, temperature, and oxygen saturation) should be monitored before, during, and after the infusion, particularly during the first several infusions and in patients who have previously experienced infusion-associated reactions.

Self-Administration at Home

After an appropriate period of supervised hospital-based infusions during which the patient demonstrates good tolerability, home infusion may be considered for suitable patients. The decision to transition to home infusion should be made jointly by the patient and the treating physician, taking into account the patient's clinical stability, infusion history, and ability to manage the infusion process. Patients and their caregivers must receive comprehensive training covering the preparation of the infusion, aseptic technique, intravenous access, operation of the infusion pump, recognition and management of infusion reactions, and when to seek emergency medical help.

Home infusion should only proceed if the patient has tolerated a sufficient number of hospital-based infusions without significant adverse events. Emergency medications (including epinephrine and corticosteroids) should be readily available during home infusions. Patients administering Replagal at home should maintain a log of each infusion, including any adverse events, and report these to their treating physician at regular follow-up visits.

Missed Doses

If a dose is missed, the next infusion should be administered as soon as possible, and subsequent infusions should then resume at the regular every-two-week schedule. The dose should not be doubled to make up for a missed infusion. Regular adherence to the infusion schedule is important for maintaining consistent enzyme levels and optimal therapeutic benefit. Extended treatment interruptions may lead to deterioration in clinical status, and patients should discuss any planned or unplanned interruptions with their physician.

What Are the Side Effects of Replagal?

Like all medicines, Replagal can cause side effects, although not everybody gets them. The majority of adverse events associated with Replagal are infusion-associated reactions (IARs), which are most common during the initial months of treatment. These reactions are thought to be mediated by both IgE-dependent (true allergic) and non-IgE-dependent (anaphylactoid or complement-mediated) mechanisms. With continued treatment, the frequency and severity of infusion reactions generally decrease, although they may recur intermittently throughout the course of therapy.

The side effects are classified below according to how often they occur, based on clinical trial data and post-marketing surveillance reports. These frequency categories follow the internationally standardized MedDRA convention used by regulatory agencies worldwide.

Infusion-associated reactions typically occur during the infusion or within the first few hours after completion. The mechanisms underlying these reactions are complex and may involve IgG and IgE antibody-mediated processes, complement activation, and direct mast cell degranulation. Patients who develop IgG antibodies to agalsidase alfa may experience more frequent or more severe infusion reactions, though the relationship between antibody status and infusion reactions is not straightforward.

The cardiac adverse events listed under the "not known" frequency category (cardiac ischemia and heart failure) have been reported predominantly in patients with significant pre-existing Fabry cardiomyopathy. In these patients, the cardiac manifestations of the underlying disease make it difficult to determine whether the events were related to the infusion or to the natural progression of the disease. Nevertheless, patients with known cardiac involvement should be carefully monitored during infusions, and a lower infusion rate may be considered if there are concerns about cardiac tolerance.

Long-term safety data from clinical trials and registry studies spanning more than 10 years of treatment indicate that the overall safety profile of Replagal remains favorable with continued use. The frequency of infusion-associated reactions tends to decrease during the first year of treatment, and many patients who initially experience reactions eventually tolerate infusions without significant adverse events. Immune tolerance has been observed in some patients who initially developed antibodies, with antibody titers declining or becoming undetectable over time.

How Should You Store Replagal?

Proper storage of Replagal is essential to maintain the stability and effectiveness of the protein-based medication. Agalsidase alfa is a recombinant enzyme that is sensitive to temperature extremes, light exposure, and physical agitation, all of which can cause protein denaturation and loss of enzymatic activity.

Unopened vials of Replagal should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F to 46°F). The vials must not be frozen, as freezing can cause irreversible damage to the protein structure. If a vial has been accidentally frozen, it should not be used and should be discarded appropriately. The vials should be kept in the original outer carton to protect the contents from light, as prolonged light exposure may degrade the protein.

Once the concentrate has been withdrawn from the vials and diluted in 100 ml of 0.9% sodium chloride solution, the resulting infusion solution should be used immediately. If immediate use is not possible, the diluted solution may be stored for up to 24 hours at 2-8°C. From a microbiological standpoint, since the product does not contain preservatives, immediate use after dilution is strongly recommended to minimize the risk of microbial contamination. The infusion solution should not be stored at room temperature for extended periods.

Before administration, the diluted solution should be inspected visually. Do not use the solution if it appears cloudy, contains visible particles, or is discolored. The solution should be clear to slightly opalescent and colorless to pale yellow. Do not use the product after the expiry date printed on the vial label and outer carton. Keep this medicine out of the sight and reach of children. Do not dispose of unused medicine via household waste or wastewater; ask your pharmacist about proper disposal in accordance with local regulations.

What Does Replagal Contain?

Active Substance

The active substance in Replagal is agalsidase alfa, a recombinant form of human alpha-galactosidase A. It is produced using gene-activation technology in a continuous human cell line. Each milliliter of concentrate contains 1 mg of agalsidase alfa, and each 3.5 ml vial contains a total of 3.5 mg. The recombinant enzyme has the same amino acid sequence and similar glycosylation profile as the naturally occurring human enzyme, which is critical for proper cellular uptake via mannose-6-phosphate receptors and delivery to lysosomes where it exerts its therapeutic effect.

Excipients

The formulation contains the following inactive ingredients (excipients) that serve as stabilizers and buffers to maintain the protein in its active conformation:

• Sodium chloride: Used as a tonicity agent to make the solution isotonic with blood
• Sodium dihydrogen phosphate monohydrate: Used as a buffering agent to maintain the appropriate pH
• Polysorbate 20: A non-ionic surfactant that helps prevent protein aggregation and adsorption to surfaces
• Water for injections: The solvent for the formulation